Joerg Thomas Epplen

Joerg Thomas Epplen

Auto-generated profile, based on publicly available information

Joerg Thomas Epplen

Amedes Genetics Hannover Germany

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
RRR. H.S.R. Roxburgh
R. H.S.R. Roxburgh
SSS. R. Seaman
S. R. Seaman
TMT. Masterman
T. Masterman
AHA. E. Hensiek
A. E. Hensiek
SSS. J. Sawcer
S. J. Sawcer
DCD.A.S. Compston
D.A.S. Compston
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.

27 July 2003 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FRFrank Rutsch
Frank Rutsch
NRNico Ruf
Nico Ruf
SVSucheta Vaingankar
Sucheta Vaingankar
MTMohammad R. Toliat
Mohammad R. Toliat
ASAnita Suk
Anita Suk
PNPeter Nürnberg
Peter Nürnberg

1 December 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SHSusan E Holmes
Susan E Holmes
EOElizabeth E O'HEarn
Elizabeth E O'HEarn
MMMelvin G McInnis
Melvin G McInnis
DGDaniel A Gorelick-Feldman
Daniel A Gorelick-Feldman
JKJohn J Kleiderlein
John J Kleiderlein
RMRussell L Margolis
Russell L Margolis

1 December 1997 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LSLudger Schöls
Ludger Schöls
GAGeorgios Amoiridis
Georgios Amoiridis
TBThomas Büttner
Thomas Büttner
HPHorst Przuntek
Horst Przuntek
JEJörg T. Epplen
Jörg T. Epplen
OROlaf Riess
Olaf Riess

1 April 1988 in Nature
Verified
Journal Article
Closed access
DSDeming Sun
Deming Sun
YQYufen Qin
Yufen Qin
JCJohanna Chluba
Johanna Chluba
JEJörg T. Epplen
Jörg T. Epplen
HWHartmut Wekerle
Hartmut Wekerle

1 October 1990 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MPM Pette
M Pette
KFK Fujita
K Fujita
DWD Wilkinson
D Wilkinson
DADanny M Altmann
Danny M Altmann
JTJ Trowsdale
J Trowsdale
HWH Wekerle
H Wekerle
A panel of 20 human myelin basic protein (hMBP)-specific T-lymphocyte lines was generated from the peripheral blood of eight multiple sclerosis (MS) patients and two healthy donors, most of them expressing the HLA-DR2 haplotype, which is associated with an increased susceptibility to MS. Using HLA-DR gene-transfected mouse L-cell lines as antigen-presenting cells, we established that of the 20 hMBP-specific T-lymphocyte lines, 7 were restricted by the DR2a gene products of the DR2Dw2 haplotype. Four T-cell lines recognized hMBP in the context of the DR2b products of the DR2Dw2 haplotype. DR2b-restricted T-cell responses were demonstrable only in T-cell lines derived from MS patients. The hMBP epitopes presented by the DR2a heterodimer were mapped to peptides covering amino acid residues 1-44, 76-91, 131-145, or 139-153 and to a region spanning the thrombin-cleaved bond at Arg130-Ala131. DR2b-restricted T-cell lines recognized epitopes within amino acids 80-99 and 148-162. Peptide 139-153 was also presented in the context of HLA-DR1 molecules. Our data show that (i) in MS patients both the DR2a and DR2b products of the DR2Dw2 haplotype function as restriction elements for the myelin autoantigen hMBP, (ii) the DR2a molecule presents at least five different epitopes to hMBP-specific T lymphocytes, and (iii) anti-hMBP T-cell lines derived from individual donors can differ in their antigen fine specificity as well as in their HLA restriction.